**Core tip:** Gastrostomy is an established method for enteral nutrition of patients, but according to our experience and clinical studies, the wrong patients are often supplied with tube feeding. In addition to patients with clear indications, patients with advanced dementia receive gastrostomies for long-term-feeding. More data are needed for indication and timing of tube implantation, not only in demented patients.

INTRODUCTION
============

The method of percutaneous endosocopic gastrostomy (PEG) as a tool for enteral nutrition was first described in 1980 by Gauderer et al\[[@B1]\]. Since then, PEG has evolved as the method of choice in patients with apparent or imminent long-term restriction of oral nutrition. Gastrostomy is easy to install percutaneously using translucency during gastroscopy. The tube needs some care, which is largely standardized and, if necessary, can be easily removed by simple gastroscopy.

When a technique comes of age, it is time to review its current practice as well as the indications for and complications of this intervention. Is enteral nutrition indeed superior to parenteral nutrition? Are patients who receive a gastrostomy appropriately chosen for this intervention? Do we need more data to assess the usefulness of PEG in certain situations?

ENTERAL *VS* PARENTERAL NUTRITION
=================================

There is ample evidence from experimental and clinical studies that enteral nutrition (orally or *via* a tube) confers many positive effects in comparison to parenteral nutrition. These effects include preservation of the intestinal mucosal barrier, reduction of intestinal and other infections and improvement of the overall prognosis of patients with long-term artificial nutrition\[[@B2]-[@B7]\]. Additionally, parenteral nutrition requires administration of lipid formulations *via* a port system, which promotes port infections and septic complications. In a meta-analysis comprising almost 4000 patients who had undergone surgery for gastrointestinal (GI) tumors, parenteral nutrition was associated with a significantly higher rate of infectious and noninfectious complications\[[@B8]\]. In a very recent Japanese study, enteral nutrition *via* PEG was associated with a significantly longer survival (median survival of 317 *vs* 195 d) compared to parenteral nutrition in older patients with dysphagia\[[@B9]\]. Therefore, as far as it is technically and functionally feasible, enteral nutrition is preferable to parenteral nutrition. This is also emphasized by the ESPEN guideline for ethical aspects of artificial nutrition, which recommends enteral over parenteral nutrition in order "to support intestinal functions to the greatest possible extent"\[[@B10]\].

COMPLICATIONS AND TYPE OF ACCESS AND TUBE
=========================================

Several large case series have investigated complication rates in PEG patients. Severe complications during or immediately after gastrostomy are rare (1.8%) and include bleeding, perforation and peritonitis\[[@B11]\]. Late complications occur in approximately 5% of patients and are mostly associated with nursing failures, leading to tube leakage or blockage, mucosal overgrowth of the retaining plate in the stomach ("buried bumper") or aspiration. Mild local infections at the tube insertion site have been reported in approximately 11% of cases\[[@B11],[@B12]\] and require only local treatment. More recent studies have reported severe complications (acute and during feeding) in 3.8%--10% of PEG patients\[[@B13],[@B14]\]. Patients with dementia did not have significantly more complications than those without dementia in one large study\[[@B15]\], but this remains controversial.

To ensure maximal effect of enteral nutrition *via* tube feeding, before gastrostomy, basic considerations are necessary for each individual case to check suitability of the patient and the clinical situation for this intervention (see Table [1](#T1){ref-type="table"}). These considerations should also encompass alternative interventions such as metal stents or surgical procedures.

###### 

Basic considerations for percutaneous endoscopic gastrostomy implantation and typical access types

  ---------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------
  **Basic considerations for PEG implantation**                                                                                                  
  Is oral nutrition - for whatever reason - so inadequate that intervention is justified?                                                        
  Is enteral nutrition likely to be necessary for at least 3 wk?                                                                                 
  Is the intestine distal to the access path functional?                                                                                         
  Are risk factors for complications absent?                                                                                                     
  Is the anatomy suitable for PEG?                                                                                                               
  Is compliance sufficient for PEG handling (feeding in (half) upright position, infection prophylaxis, mobilization of the PEG tube, *etc*.)?   
  **Typical access types**                                                                                                                       
  Pull-PEG (Ponsky-Gauderer)                                                                                                                     After diaphanoscopy, primary puncture with a trocar followed by pulling the tube with a thread through the esophagus
  Push-/Introducer-PEG (Russell)                                                                                                                 With diaphanoscopy, primary gastropexy followed by direct introduction of a balloon-fixed tube
  ---------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------

PEG: Percutaneous endoscopic gastrostomy.

The pull method is the standard procedure for gastrostomy and tube implantation. Since 2000, a push-/introducer-PEG method has also been possible; this method is extremely attractive for patients with pharyngeal or esophageal tumor stenosis precluding gastroscopic access to the stomach\[[@B16]\]. However, in our clinical experience as well as according to existing data, whenever possible, the pull-PEG method should be preferred due to lower complication rates and better handling\[[@B17],[@B18]\].

ACCEPTED INDICATIONS FOR GASTROSTOMY
====================================

Percutaneous endoscopic gastrostomy has been established as a treatment option for transient or permanent dysphagia due to neurologic disorders, *e.g*., stroke\[[@B19],[@B20]\]. In the same way, patients with oncological diseases of the mouth and throat as well as the esophagus can benefit from a temporary PEG tube during multimodal therapy, especially during radiotherapy. Ensuring adequate nutrition allows the therapy to be carried out in a timely manner and at full dose by preventing weight loss and, thus, ultimately improves patient prognosis\[[@B21]\] (Table [2](#T2){ref-type="table"}).

###### 

Accepted and data-supported indications for percutaneous endoscopic gastrostomy (for references see text)

  **Main disease groups**                                                                                            **Diagnosis/reason for dysphagia**
  ------------------------------------------------------------------------------------------------------------------ ------------------------------------
  Cancer                                                                                                             Head and neck cancer
  Pharyngeal cancer                                                                                                  
  Esophageal carcinoma                                                                                               
  Cancer with functional bowel obstruction (percutaneous endoscopic gastrostomy used as a decompression measure)     
  Neurodegenerative disorders                                                                                        Stroke
  Amyotrophic lateral sclerosis                                                                                      
  Multiple sclerosis                                                                                                 
  Severe brain damage from various reasons (trauma, persistent vegetative state, psychomental retardation, *etc*.)   

DEMENTIA -- THE MOST DOUBTFUL INDICATION FOR GASTROSTOMY
========================================================

Patients with degenerative cerebral diseases, above all dementia, have increasingly received gastrostomies and represented in some studies and regions the largest group of tube feeded patients\[[@B22]-[@B24]\]. Given the lack of evidence for a benefit in this patient group, this issue generates debates already for decades. In a time with an increasing economic health burden, a necessity to improve the efficiency of health care in an aging society and health care workers often pressed for time, this development is understandable but must be viewed with great skepticism.

Frequently, the indication of gastrostomy is the result of an acute deterioration in the health state and/or expression of a state of emergency in caring for these patients. Occasionally, cultural or religious reasons also play a role when relatives do not approve limiting therapy, although the quality of life is already dramatically reduced, and the prognosis is limited. Sometimes, gastrostomy is advocated because people caring for the patient, including their physicians, are unable to cope with difficult nursing and medical situations.

Comfort feeding\[[@B25]\] is propagated as an alternative to artificial nutrition, but this approach requires more human resources, is very cost-intensive and probably cannot be executed in high numbers in today\'s care structures. From a practical point of view, it is understandable that gastrostomy is performed to keep processes and personnel structures within affordable limits in a nursing home, but this approach often does not meet the needs of the patient. Eventually, gastrostomy, as well as long-term tube feeding, carry similar risks as other interventional measures\[[@B26],[@B27]\]; additionally, it may detain patients from the pleasures of tasting and of social contacts. Furthermore, advanced dementia patients tend to manipulate access points and tubes and thereby are prone to injure themselves. A risk-benefit analysis is therefore particularly important in any patient group and should be provided to the patient and/or his relatives.

The wish of supporting the nutrition of demented patients using tube feeding leads to a high rate of gastrostomies in patients with already advanced disease. Often these patients already suffer from progressive malnutrition and immobility. In many studies with demented patients, the complication rate of gastrostomy is unacceptably high\[[@B28],[@B29]\]. We and others think that this is more related to patient factors than an innate risk of the intervention\[[@B30]\]. This view is supported by data from studies showing that control patients (with no PEG) had a very similar or even worse mortality\[[@B29],[@B31]\], and patients with only mild dementia had a significant higher benefit than those with advanced dementia\[[@B28]\].

We call this the PEG paradox -- choosing the patients too late for the intervention leads to missing benefit and greater harm including higher morbidity and mortality.

A Cochrane systematic review conducted in 2009 did not find a single randomized controlled trial that investigated the benefits of tube feeding in patients with dementia\[[@B32]\]. Consequently, recent guidelines do not encourage gastrostomy in patients with advanced dementia\[[@B33]\], although clear and high-quality data in this clinical field are lacking. Table [3](#T3){ref-type="table"} shows the recent studies that examined the effects of tube feeding in patients with dementia\[[@B34]-[@B39]\]. Reviews and meta-analyses\[[@B40]-[@B42]\] mostly identified two severe problems of PEG studies in dementia patients. First, no randomized, prospective, properly controlled studies have been conducted. Most available studies have retrospective designs and suffer from a huge selection bias, and control groups are poor or unmatched. Second, in most studies, patients with dementia are not properly staged and are treated as a homogenous patient group. This prevents the identification of subgroups (*e.g*., patients with only mild to moderate dementia) that might benefit from enteral nutrition *via* tube feeding. Other problems include poor exclusion and inclusion criteria, inappropriate outcome measures and small sample sizes\[[@B42]\].

###### 

Studies of enteral nutrition with dementia patients in recent years

  **Ref**.                                   **Design**                               **Number of patients with dementia**                       **Main results**                                                                              **Study problems/Appraisal**
  ------------------------------------------ ---------------------------------------- ---------------------------------------------------------- --------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------
  Higaki et al\[[@B15]\], 2008               Retrospective cohort study               311 (143 with and 168 w/o dementia)                        No significant differences in survival                                                        No controls w/o PEG
  Suzuki et al\[[@B28]\], 2012               Observational study                      1353                                                       Significantly more benefit in patients with early dementia                                    Endpoint "Level of independent living of demented elderly" not validated, no controls
  Ticinesi et al\[[@B34]\], 2016             Observational study                      184 (54 with PEG, 130 w/o PEG)                             Survival with PEG significantly worse                                                         Selection bias, no basic data for PEG-group *vs* non-PEG-group, patients with advanced dementia had better results compared to those with early dementia
  Nunes et al\[[@B35]\], 2016                Retrospective observational study        46 (only CDR 2 and 3)                                      Low albumin, transferrin and cholesterol as predictors for poor survival                      No controls
  Cúrdia et al\[[@B36]\], 2017               Prospective cohort study, uncontrolled   26 (out of 60 in the whole cohort)                         Significant decrease in hospitalization and visits to ER, \> 50% healing of pressure ulcers   Only internal controls, no dementia grading
  Ayman et al\[[@B37]\], 2017                Retrospective cohort                     165, control group with PEG for other reasons              Significantly shorter survival in dementia patients                                           No dementia control group, no dementia rating
  Gingold-Belfer et al\[[@B38]\], 2017       Retrospective Cohort, uncontrolled       189                                                        Albumin level associated with longer survival (at baseline as well as during observation)     No control group, no dementia rating
  Van Bruchem-Visser et al\[[@B39]\], 2019   Retrospective cohort                     42 (out of 303 in the whole cohort), no controls w/o PEG   Survival with PEG significantly shorter in patients with dementia                             Selection bias, no dementia rating, PEG-indication partly unclear

w/o: Without; ER: Emergency room; PEG: Percutaneous endoscopic gastrostomy.

NON-NEUROLOGICAL PATIENT GROUPS WITH POSSIBLE BENEFIT
=====================================================

In our opinion and clinical experience, there are other patient groups in clinical medicine that could benefit significantly from early gastrostomy. Even though it is hardly supported by study data, patients with chronic pancreatitis and pronounced (postprandial) pain syndrome often benefit from tube feeding that prevents weight loss, maintains mobility and physical activity, and thus, improves their quality of life. In our clinical experience, pulmonary cachexia in chronic obstructive pulmonary disease (COPD) patients can also be either avoided or alleviated by early PEG application. Although COPD has been identified as a risk factor for early mortality in patients with a PEG tube for other indications\[[@B43]\], there is not a single study investigating the effect of early enteral nutrition in patients with COPD who manifest cachexia or are at risk for malnutrition. In many cancers, even cancer outside the GI tract such as lung, prostate and hematological tumors, malnutrition is frequent\[[@B44]\] (Table [4](#T4){ref-type="table"}). Early and consistent enteral nutrition can enable timely and dose-appropriate chemotherapy and thus improve prognosis, since weight loss is one of the main risk factors for premature death in many cancers\[[@B45]-[@B47]\]. At least for the quality of life endpoint, this has already been shown in several studies\[[@B48]\], but proof for hard endpoints such as overall survival is currently lacking.

###### 

Additional patient groups with a lack of data but potential benefit if the timing of gastrostomy is correct

  --------------------------------------------------------
  Chronic pancreatitis
  COPD with manifest or imminent undernutrition/cachexia
  Severe eosinophilic esophagitis
  Severe ulcerative reflux disease
  Cancer with undernutrition syndrome
  (Mild to) moderate dementia
  --------------------------------------------------------

COPD: Chronic obstructive pulmonary disease.

It is also conceivable that patients with other severe diseases (such as ulcerative reflux disease or severe eosinophilic esophagitis) may also benefit from gastrostomy, even if they are young. However, supporting data are lacking. Therefore, physicians are often reluctant to consider gastrostomy in these otherwise healthy and, often, young patients. At present, such decisions must remain extremely individualized. To what extent an intermittent PEG system in this patient population can contribute to the maintenance of a certain body weight and, thus, help to avoid physical weakness should be the subject of future studies. Nevertheless, data regarding the prognosis of such patients with or without enteral nutrition are quite important and economically and individually relevant; for example, for employment biographies.

TIMING OF GASTROSTOMY
=====================

In the neurological field, gastrostomy also represents an important therapeutic option for patients with amyotrophic lateral sclerosis (ALS), depending on the overall situation and the preference of these patients\[[@B19]\], who are conscious until their death. Weight loss in these patients is present very often, even without dysphagia\[[@B49]\]. Recent data also indicate that the time of tube insertion should be advanced compared to the current approach\[[@B50]\]. Patients with ALS had a significant better survival if enteral nutrition was initiated before the presence of weight loss\[[@B49]\]. To date, this aspect of the \"timing\" of gastrostomy has been disregarded. Earlier continuous enteral nutrition has the potential to improve prognosis significantly and should be considered in future studies. "Early" in this respect would mean gastrostomy before the underlying disease (regardless whether neurological or non-neurological) has caused significant malnutrition and weight loss accompanied by catabolism or restricted mobility. Here, the GLIM criteria can play an important role (with the underlying disease as etiologic criterion and a clear cut anticipatory definition of the phenotypic criterion)\[[@B51]\]. Timing of the intervention by such criteria would improve the patient selection and reduce the complication rate. With early gastrostomy, the prevalence of low albumin, higher age and higher comorbidity (all risk factors for worse outcome\[[@B29]\]) would be lower in patients selected for this intervention.

This may close the circle of argumentation in the case of patients with dementia; much more than before, gastroenterologists must also learn to assess patients with chronic degenerative cerebral diseases. These diseases will increase substantially during the next decades. In patients with very advanced stages of dementia with complete immobility, lack of speech production and contractures, a gastrostomy is probably more harm- than useful. However, patients with early or moderate dementia, for whom we have not thought about enteral feeding so far, could possibly benefit from tube feeding.

Early tube feeding could prevent the progressive immobility of dementia patients and, thus, preserve their quality of life for longer. Data regarding these patients are extremely scarce (see discussion above), but a few subgroup analyses as well as some studies with better defined patient groups support this view\[[@B28],[@B36],[@B52]\]. In a large Japanese study, the selection of patients with early or moderate dementia increased the proportion of patients with a benefit as measured by the level of independent living four times as compared to patients with advanced dementia\[[@B28]\].

However, in studies regarding nutritional support for dementia patients, no general benefits were obtained in cognitive tests\[[@B33]\]. Therefore, while dementia cannot be stopped, mobility and quality of life may be maintained longer. To date, due to this poor data situation, tube feeding and parenteral nutrition have only been recommended "to overcome a crisis situation" and "for a limited time" in the guidelines for this group of patients overall, and not at all or only as "very rare exception" for patients in late stages\[[@B33]\].

CONCLUSION
==========

In our opinion, we must therefore pay attention to the following: Patients with dementia in very advanced stages should no longer be treated with artificial nutrition of any kind. We must explain this to the relatives and referring doctors. We must draw their attention to the data that suggest more and more severe complications in these patients than in less seriously ill patients as well as to the missing benefit for these patients. On the other hand, we may have to think about tube feeding at an earlier stage for patients at nutritional risk due to temporary or chronic restrictions of oral feeding. These patients should be made more consistently aware of the possibility of a gastrostomy before weight loss or even catabolism has occurred. This can affect younger, otherwise completely healthy patients as well as dementia patients in an earlier, still mobile stage.

In summary, while there may not necessarily be a current under- or over-utilization of PEG, there is a need to improve patient selection. To achieve this goal, we need more prospective randomized controlled studies to better define the indications for PEG in the patient groups and conditions outlined above.
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